- Companies
- Aphea.Bio
Aphea.Bio Funding, Investors & Competitors
Aphea.Bio has raised $112M across 4 funding rounds, most recently a $77M Series C in July 2023.
Last Aphea.Bio funding round
$77M
Series C · Jul 2023
Cumulative funding Aphea.Bio raised
$112M
across 4 funding rounds
Key investors in Aphea.Bio
Agri Investment Fund
PMV
V-Bio Ventures
Gemma Frisius Fund
VIVES Funds
European Circular Bioeconomy Fund
VIB
Astanor Ventures
About Aphea.Bio
Aphea.Bio is a Belgium-based developer of biopesticides and biostimulants using natural microorganisms. The company produces crop protection products as alternatives to chemical pesticides and growth enhancers that improve nutrient uptake in soil. Aphea.Bio targets row crops like potatoes, sugar beets, and vegetables across Europe with field-tested formulations.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Sectors
Aphea.Bio Funding History
Aphea.Bio has raised a total of $112M across 4 funding rounds.
Aphea.Bio's first fundraising round was a $9M Series A in June 2017. The most recent completed round was a $77M Series C in July 2023.
Aphea.Bio funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Jul 2023 | Series C | Innovation Industries (lead); SFPI-FPIM; European Circular Bioeconomy Fund; Astanor Ventures; Bill & Melinda Gates Foundation; Korys; BNP Paribas Fortis; Agri Investment Fund; V-Bio Ventures | $77M | Aphea.Bio is a Belgium-based agricultural biotechnology company founded in 2017 that develops next-generation biological products based on naturally occurring microorganisms. The company focuses on biostimulant and biocontrol solutions designed to reduce fertilizer application and control fungal diseases in maize and wheat, offering sustainable alternatives to chemical fertilizers and pesticides. Aphea.Bio successfully closed a Series C funding round on July 11, 2023, raising €70 million (approximately $77 million USD). The round was led by Innovation Industries and included participation from Korys Investments, the Bill & Melinda Gates Foundation, SFPIM, BNP Paribas Fortis, and returning investors including the European Circular Bioeconomy Fund, Astanor, and the Agri Investment Fund. At the time of the Series C, Aphea.Bio had grown into a team of over 50 scientists and industry specialists, with a new pilot plant set to open in late 2023, and had recently achieved Certified B Corporation status. The funding was designated to advance research and development in biologicals, scale product launches, expand market reach, and commercialize product offerings, with specific support from the Gates Foundation for developing biostimulant products aimed at smallholder farmers in Sub-Saharan Africa and South Asia. By May 2024, the company had submitted applications for regulatory approval of its first biofungicides, VALORIA and VIRTUOSA, to the EPA in the United States, demonstrating progress toward commercialization of its product pipeline. |
| Apr 2021 | Series B | Astanor Ventures (lead); Gemma Frisius Fund; QBIC II; European Circular Bioeconomy Fund; PMV; VIVES Funds; Agri Investment Fund; V-Bio Ventures; VIB | $22M | Aphea.Bio, a Gent, Belgium-based spin-off from VIB, Ghent University, and K.U. Leuven founded in December 2016, develops next-generation agricultural biologicals using natural microorganisms from the plant microbiome to create biostimulants that reduce fertilizer use and biofungicides to control fungal diseases in row crops like maize and wheat. The company employs an innovative discovery platform combining proprietary technologies to analyze microbial collections and identify beneficial strains. On April 14, 2021, the European Circular Bioeconomy Fund (ECBF) invested in Aphea.Bio, expanding its Series B financing round to a total of €18 million, following an initial €14 million tranche led by Astanor Ventures that closed in October 2020. ECBF invested on par with Astanor, with participation from existing investors including Agri Investment Fund, PMV, QBIC II, V-Bio Ventures, VIB, and Vives Louvain Technology Fund, matching the specified investor list. The funding supports advancing the portfolio of biostimulant and biofungicide products toward regulatory approval and initial commercial entry, substituting chemical inputs with sustainable natural alternatives to promote a transition to more sustainable agriculture. Aphea.Bio later raised a €70 million Series C round on July 11, 2023, led by Innovation Industries with support from Korys, Bill & Melinda Gates Foundation, SFPIM, BNP Paribas Fortis, and returning investors like ECBF and Astanor, to advance R&D, scale product launches, expand markets, and develop solutions for smallholder farmers in Sub-Saharan Africa and South Asia. |
| Apr 2021 | Series B | Gemma Frisius Fund; European Circular Bioeconomy Fund; PMV; VIVES Funds; Agri Investment Fund; Qbic Fund; VIB | $5M | - |
| Jun 2017 | Series A | V-Bio Ventures (lead); Gemma Frisius Fund; PMV; The Group Ceuster; VIVES Funds; Agri Investment Fund; Qbic Fund; VIB | $9M | Aphea.Bio, a Belgium-based biopesticides spinout from VIB, KU Leuven, and Ghent University, raised €7.7 million ($8.7 million) in a Series A round on June 26, 2017, led by V-Bio Ventures with participation from Agri Investment Fund, Gemma Frisius Fund, PMV, Qbic Fund, The Group Ceuster, VIB, and Vives Louvain Technology Fund. In total, the company raised 7.7 million euros in capital and 1.3 million euros in non-dilutive capital around this time. This funding supported the development of innovative biological products for sustainable agriculture, focusing on biostimulants and biocontrols to enhance crop protection and soil vitality. |
Who has invested in Aphea.Bio?
16 investors have backed Aphea.Bio across its funding rounds, including Agri Investment Fund, PMV, V-Bio Ventures, Gemma Frisius Fund, VIVES Funds and European Circular Bioeconomy Fund.
Lead investors include Innovation Industries, Astanor Ventures and V-Bio Ventures.
Aphea.Bio Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Participant | Jun 2017 | ||
| 3 | Participant | Jun 2017 | ||
| 3 | Participant | Apr 2021 | ||
| 3 | Participant | Jun 2017 | ||
| 3 | Participant | Jun 2017 | ||
| 3 | Lead | Jun 2017 | ||
| 3 | Participant | Jun 2017 | ||
| 2 | Lead | Apr 2021 | ||
| 2 | Participant | Jun 2017 | ||
| 1 | Participant | Jul 2023 | ||
| 1 | Participant | Apr 2021 | ||
| 1 | Participant | Jul 2023 | ||
| 1 | Participant | Jul 2023 | ||
This data is available for Pro users. Sign up to see all 16 Aphea.Bio investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAphea.Bio Competitors
Aphea.Bio competitors include listed companies like Corteva, BASF, Archer-Daniels-Midland and Nutrien, and private ones like Meicai and Farmers Business Network.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $17B | $2.9B | $54B | 3.2x | ||
| Publicly listed | $69B | $8.2B | $52B | 1.0x | ||
| Publicly listed | $80B | $2.9B | $42B | 0.6x | ||
| Publicly listed | $27B | $6.1B | $38B | 1.8x | ||
| Private | - | - | $7B | - | ||
| Private | - | - | $4B | - |
Aphea.Bio Public Comps
Aphea.Bio is still privately-owned, but its public comps include Corteva, BASF, Archer-Daniels-Midland, Nutrien, Muyuan Foods, Novonesis, Bunge, CF Industries, Qinghai Salt Lake Industry and Wilmar International.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $17B | $2.9B | 3.3x | 3.2x | 19.5x | 13.9x | |||
| $69B | $8.2B | 1.1x | 1.0x | 8.9x | 8.6x | |||
| $80B | $2.9B | 0.6x | 0.6x | 17.4x | 11.2x | |||
| $27B | $6.1B | 1.9x | 1.8x | 8.2x | 8.0x | |||
| $21B | $5B | 2.0x | 2.3x | 8.7x | 16.1x | |||
| $4.8B | $1.6B | 7.1x | 6.7x | 21.7x | 17.9x | |||
| $70B | $2.3B | 0.6x | 0.5x | 17.9x | 11.2x | |||
| $7.1B | $3.2B | 3.5x | 3.1x | 7.7x | 6.8x | |||
This data is available for Pro users. Sign up to see all Aphea.Bio competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Aphea.Bio
| When was Aphea.Bio founded? | Aphea.Bio was founded in 2017. |
| Where is Aphea.Bio headquartered? | Aphea.Bio is headquartered in Ghent, Belgium. |
| Is Aphea.Bio publicly listed? | No, Aphea.Bio is a private, VC-backed company. |
| How much funding has Aphea.Bio raised? | Aphea.Bio has raised $112M across 4 funding rounds. |
| What was Aphea.Bio's last funding round? | Aphea.Bio's last funding round was a $77M Series C in July 2023, led by Innovation Industries. |
| Who are Aphea.Bio's investors? | Aphea.Bio's investors include Agri Investment Fund, Gemma Frisius Fund, European Circular Bioeconomy Fund, PMV, VIVES Funds, V-Bio Ventures, VIB, Astanor Ventures, Qbic Fund, SFPI-FPIM and 6 others. |
| Which companies are comparable to Aphea.Bio? | Companies comparable to Aphea.Bio include Corteva, BASF, Archer-Daniels-Midland, Nutrien, Meicai and Farmers Business Network. |
See companies similar to Aphea.Bio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




